Post Menopausal Osteoporosis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Post Menopausal Osteoporosis – Pipeline Review, H1 2020’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis

– The report reviews pipeline therapeutics for Post Menopausal Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Post Menopausal Osteoporosis therapeutics and enlists all their major and minor projects

– The report assesses Post Menopausal Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ablynx NV

AlphaMab Co Ltd

Amgen Inc

Aryogen Pharmed Co

Entera Bio Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Epygen Biotech Pvt Ltd

Genor BioPharma Co Ltd

Hengenix Biotech Inc

Hualan Biological Engineering Inc

InSight Biopharmaceuticals Ltd

Intas Pharmaceuticals Ltd

Ipsen SA

JHL Biotech Inc

Jiangsu T-mab BioPharma Co Ltd

Lupin Ltd

Luye Pharma Group Ltd

Metabolab Inc

Nano Intelligent Biomedical Engineering Corp

Nanomedic Inc

NeuClone Pty Ltd

Paras Biopharmaceuticals Finland Oy

Qilu Pharmaceutical Co Ltd

Reliance Life Sciences Pvt Ltd

Sandoz International GmbH

Shandong Danhong Pharmaceutical Co Ltd

Shanghai Biomabs Pharmaceuticals Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Uni-Bio Science Group Ltd

USV Pvt Ltd

Table of Contents

Table of Contents

Introduction

Post Menopausal Osteoporosis - Overview

Post Menopausal Osteoporosis - Therapeutics Development

Post Menopausal Osteoporosis - Therapeutics Assessment

Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development

Post Menopausal Osteoporosis - Drug Profiles

Post Menopausal Osteoporosis - Dormant Projects

Post Menopausal Osteoporosis - Discontinued Products

Post Menopausal Osteoporosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Post Menopausal Osteoporosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Post Menopausal Osteoporosis – Pipeline by Ablynx NV, H1 2020

Post Menopausal Osteoporosis – Pipeline by AlphaMab Co Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Amgen Inc, H1 2020

Post Menopausal Osteoporosis – Pipeline by Aryogen Pharmed Co, H1 2020

Post Menopausal Osteoporosis – Pipeline by Entera Bio Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Enteris BioPharma Inc, H1 2020

Post Menopausal Osteoporosis – Pipeline by Enzene Biosciences Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Epygen Biotech Pvt Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Genor BioPharma Co Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Hengenix Biotech Inc, H1 2020

Post Menopausal Osteoporosis – Pipeline by Hualan Biological Engineering Inc, H1 2020

Post Menopausal Osteoporosis – Pipeline by InSight Biopharmaceuticals Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Intas Pharmaceuticals Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Ipsen SA, H1 2020

Post Menopausal Osteoporosis – Pipeline by JHL Biotech Inc, H1 2020

Post Menopausal Osteoporosis – Pipeline by Jiangsu T-mab BioPharma Co Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Lupin Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Luye Pharma Group Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Metabolab Inc, H1 2020

Post Menopausal Osteoporosis – Pipeline by Nano Intelligent Biomedical Engineering Corp, H1 2020

Post Menopausal Osteoporosis – Pipeline by Nanomedic Inc, H1 2020

Post Menopausal Osteoporosis – Pipeline by NeuClone Pty Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2020

Post Menopausal Osteoporosis – Pipeline by Qilu Pharmaceutical Co Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Reliance Life Sciences Pvt Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Sandoz International GmbH, H1 2020

Post Menopausal Osteoporosis – Pipeline by Shandong Danhong Pharmaceutical Co Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Shanghai Biomabs Pharmaceuticals Co Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by Uni-Bio Science Group Ltd, H1 2020

Post Menopausal Osteoporosis – Pipeline by USV Pvt Ltd, H1 2020

Post Menopausal Osteoporosis – Dormant Projects, H1 2020

Post Menopausal Osteoporosis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Post Menopausal Osteoporosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports